BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 21345787)

  • 41. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
    Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
    J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer.
    Buvat I; Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P
    Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1628-34. PubMed ID: 22710958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
    Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
    AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation.
    Prieto E; Martí-Climent JM; Domínguez-Prado I; Garrastachu P; Díez-Valle R; Tejada S; Aristu JJ; Peñuelas I; Arbizu J
    J Nucl Med; 2011 Jun; 52(6):865-72. PubMed ID: 21571807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PET/CT pattern analysis for surgical staple line recurrence in patients with colorectal cancer.
    Shyn PB; Madan R; Wu C; Erturk SM; Silverman SG
    AJR Am J Roentgenol; 2010 Feb; 194(2):414-21. PubMed ID: 20093604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual-modality brain PET-CT image segmentation based on adaptive use of functional and anatomical information.
    Xia Y; Eberl S; Wen L; Fulham M; Feng DD
    Comput Med Imaging Graph; 2012 Jan; 36(1):47-53. PubMed ID: 21719257
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
    Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
    J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients.
    Lemke AJ; Niehues SM; Hosten N; Amthauer H; Boehmig M; Stroszczynski C; Rohlfing T; Rosewicz S; Felix R
    J Nucl Med; 2004 Aug; 45(8):1279-86. PubMed ID: 15299049
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early detection of disease progression after palliative chemotherapy in NSCLC patients by (18)F-FDG-PET.
    Tauhardt E; Reissig A; Winkens T; Freesmeyer M
    Nuklearmedizin; 2014; 53(5):197-204. PubMed ID: 24986272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
    Woff E; Hendlisz A; Garcia C; Deleporte A; Delaunoit T; Maréchal R; Holbrechts S; Van den Eynde M; Demolin G; Vierasu I; Lhommel R; Gauthier N; Guiot T; Ameye L; Flamen P
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1792-801. PubMed ID: 27072811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Usefulness of non attenuation corrected 18F-FDG-PET images for optimal assessment of disease activity in patients with lymphoma.
    Houseni M; Chamroonrat W; Basu S; Bural G; Mavi A; Kumar R; Alavi A
    Hell J Nucl Med; 2009; 12(1):5-9. PubMed ID: 19330173
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
    Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Performance of tumor growth kinetics as an imaging biomarker for response assessment in colorectal liver metastases: correlation with FDG PET.
    Seyal AR; Parekh K; Arslanoglu A; Gonzalez-Guindalini FD; Tochetto SM; Velichko YS; Yaghmai V
    Abdom Imaging; 2015 Oct; 40(8):3043-51. PubMed ID: 26353898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A region growing method for tumor volume segmentation on PET images for rectal and anal cancer patients.
    Day E; Betler J; Parda D; Reitz B; Kirichenko A; Mohammadi S; Miften M
    Med Phys; 2009 Oct; 36(10):4349-58. PubMed ID: 19928065
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
    Dimitrakopoulou-Strauss A; Strauss LG; Burger C; Rühl A; Irngartinger G; Stremmel W; Rudi J
    J Nucl Med; 2004 Sep; 45(9):1480-7. PubMed ID: 15347714
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
    Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
    Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemotherapy response evaluation in metastatic colorectal cancer with FDG PET/CT and CT scans.
    Monteil J; Mahmoudi N; Leobon S; Roudaut PY; El Badaoui A; Verbeke S; Venat-Bouvet L; Martin J; Le Brun-Ly V; Lavau-Denes S; Maubon A; Bouillet P; Pouquet M; Vandroux JC; Tubiana-Mathieu N
    Anticancer Res; 2009 Jul; 29(7):2563-8. PubMed ID: 19596929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.
    Stahl A; Ott K; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1471-8. PubMed ID: 15257418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.